New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free

Vesilute

Also known as: Lys-Glu-Asp-Leu, Khavinson eye peptide, Retinal bioregulator, Vision bioregulator

Vesilute is a tetrapeptide bioregulator (Lys-Glu-Asp-Leu) developed by Professor Vladimir Khavinson, tissue-specific for the retina and visual system. It supports retinal cell function, promotes normalization of photoreceptor protein synthesis, and is studied for age-related macular degeneration (AMD), retinal aging, and vision preservation in the elderly.

Half-Life

Short (minutes); sustained gene-regulatory effects

Route

SubQ, Oral

Category

Anti-Aging & Longevity

Key Benefits

  • Supports retinal photoreceptor cell function and survival
  • May slow progression of age-related macular degeneration
  • Reduces retinal cell apoptosis from oxidative stress and aging
  • Anti-aging effects on retinal pigment epithelium
  • Potential support in diabetic retinopathy management
  • Preserves visual acuity with aging
  • Complementary to lutein, zeaxanthin, and NAD+ in ocular health protocols

Mechanism of Action

Vesilute's tetrapeptide Lys-Glu-Asp-Leu modulates gene expression in retinal pigment epithelial cells and photoreceptors. By interacting with chromatin in retinal tissue, it normalizes protein synthesis essential for phototransduction, reduces retinal cell apoptosis, and may slow the accumulation of drusen and lipofuscin associated with AMD. Its sequence is homologous to retinal tissue proteins, conferring tissue specificity.

Dosing Protocols

Standard Khavinson Protocol

Dose
10 mg per day
Frequency
Daily for 10–30 days
Timing
Subcutaneous injection or oral (enteric-coated)
Cycle
10–30 day course, repeated 2–4x per year

Often combined with Epithalon and NAD+ in visual aging protocols. Research use only.

Calculate your draw volume

Enter your vial size and BAC water to get exact injection volumes

Calculate dose →

Side Effects

  • Generally well tolerated
  • Mild injection site reactions
  • No significant ocular adverse events reported at standard doses

Contraindications

Not FDA approved. Not a substitute for anti-VEGF therapy or standard AMD treatments. Medical oversight required for diagnosed retinal conditions.

Storage

Store at 2–8°C. Protect from moisture and light.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice. Many compounds listed are research chemicals not approved for human use. Always consult a qualified healthcare professional before starting any protocol.

Was this page helpful?

Launching soon

Build and track your protocol in Staqk

Log doses, track timing, monitor biomarkers, and manage every compound in your stack — all in one place.

Free early access updates. No spam.